Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing

FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market an

VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five

Aktis Oncology (NASDAQ:AKTS) closed at $25.00 on August 18, 2026, giving the clinical-stage radiopha

Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as t

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's str

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare hol

Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart d

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

https://www.gov.uk/government/news/mhra-approves-remibrutinib-for-adults-with-chronic-spontaneous-ur

FDA approves Novartis' Pluvicto for earlier-stage metastatic prostate cancer, nearly doubling el

Axiom Investment Management LLC purchased a new stake in shares of Novartis AG (NYSE: NVS) in the fi

Ashton Thomas Securities LLC purchased a new stake in Novartis AG (NYSE: NVS) during the undefined q

These companies' recent headwinds shouldn't lead to decreased payouts.

Entropy Technologies LP acquired a new position in shares of Novartis AG (NYSE: NVS) in the undefine

Cetera Investment Advisers grew its position in shares of Novartis AG (NYSE: NVS) by 13.5% in the fi

Novartis AG ended Q2 on a high note. Despite declining sales of Entresto, the heart failure medicine

Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.

Novartis AG (NVS) Q2 2026 Earnings Call Transcript

Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong p

Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure,

GM, MMM, NVS, NOC, HAS and DHI all outperformed expectations on their quarterly reports this morning

Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by stro

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the qu

Novartis (NYSE:NVS) reported second-quarter financial results on Tuesday. The transcript from the co

Stock futures are rising after three straight days of declines for major indexes; chip stocks are le

Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats

Companies Reporting Before The Bell • Mueller Industries (NYSE:MLI) is projected to report quarterly

Novartis (NYSE:NVS) reported quarterly earnings of $2.41 per share which beat the analyst consensus

Novartis wins traditional FDA approval for Fabhalta, a first-in-class oral treatment slowing kidney

IgAN is an autoimmune kidney disease that occurs when clumps of immunoglobulin A and antibodies are

Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors

Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen AD

https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-gener

Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while a

Novartis today announced that the European Commission (EC) has approved Itvisma® (onasemnogene abepa

Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-

Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class pr

Europe has eased deportation rules of illegal migrants in response to rising public frustration over

Curium™ is pleased to announce that it has prevailed in the patent dispute brought by Novartis subsi

Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a poten

Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endp

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

The US Supreme Court turned away appeals from six pharmaceutical companies seeking to topple the Med

White House estimates Trump's drug pricing agreements could save $529 billion in next decade, bu

Sen. Warren challenges Trump's 600% TrumpRx drug price claim using a glass of water.

PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefit

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-